These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15174956)

  • 1. Vascular biology support for the use of bevacizumab in colorectal cancer.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in the treatment of colorectal cancer.
    Mulcahy MF; Benson AB
    Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab.
    Ellis LM
    Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in the treatment of colorectal cancer.
    Cilley JC; Barfi K; Benson AB; Mulcahy MF
    Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging.
    Koukourakis MI; Mavanis I; Kouklakis G; Pitiakoudis M; Minopoulos G; Manolas C; Simopoulos C
    Am J Clin Oncol; 2007 Jun; 30(3):315-8. PubMed ID: 17551312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK
    Nat Med; 2004 Feb; 10(2):145-7. PubMed ID: 14745444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 9. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
    Ferrara N; Hillan KJ; Gerber HP; Novotny W
    Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
    Hurwitz HI; Honeycutt W; Haley S; Favaro J
    Clin Colorectal Cancer; 2006 May; 6(1):66-9. PubMed ID: 16796794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab--current status and future directions.
    Midgley R; Kerr D
    Ann Oncol; 2005 Jul; 16(7):999-1004. PubMed ID: 15939715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
    Fernando NH; Hurwitz HI
    Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
    Fernando NH; Hurwitz HI
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):39-50. PubMed ID: 12802794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bevacizumab in the treatment of metastatic colorectal cancer.
    Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
    Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
    O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
    Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.